Regenerative Medicine Biotrust
The Regenerative Medicine Biotrust enables the Center for Regenerative Medicine to collect, process and store cells and other biospecimens from individual patients. As a patient's own cells are often used as a starting point for regenerative therapies, having them readily available in the biotrust is critical.
The Regenerative Medicine Biotrust accelerates the development of new and innovative treatments by allowing faster access to samples for use in research and aiding in the sharing of results between investigators. When studying a particular health issue, researchers can use samples and health information from the biotrust. Additionally, investigators have access to technical expertise provided by biotrust technicians.
Key components of the Regenerative Medicine Biotrust include:
- Tissue and organ engineering. In the laboratory, a patient's banked cells are converted into induced pluripotent stem (iPS) cells, which are stem cells able to differentiate into nearly every cell type found in the body. These patient-specific iPS cells could eventually be used to build new tissues, or even whole organs, for that patient when he or she needs them.
- Drug response testing. To evaluate how a patient's disease responds to a particular drug before the patient receives the drug, researchers can derive iPS cells from that patient's banked cells. The iPS cells could be converted into various types of cells, all of which would be affected by the patient's disease. This would give doctors a model on which to test drug responses and determine the most effective treatment for that patient's exact disease.
- Disease modeling. By comparing stem cells derived from patients who have inherited diseases with stem cells derived from their healthy family members, banked cell lines could be used to gain new insights into the pathophysiology that contributes to disease progression in specific family members.
For more information, email the Regenerative Medicine Biotrust.